AORT vs UNH

The company exhibits a weak fundamental health with a Piotroski F-Score of just 2/9, indicating significant operational and financial concerns. Despite strong revenue growth of 18.4% and impressive recent earnings surprises, the negative profit margin (-2.16%) and negative ROE (-2.46%) reflect persistent profitability issues. Valuation metrics are stretched, with a Forward P/E of 50.97 and Price/Book of 4.65, while insider selling worth $9.73M signals management's lack of confidence. Although balance sheet liquidity is strong (Current Ratio: 3.93), the absence of Altman Z-Score and weak earnings quality undermine long-term sustainability.

UnitedHealth Group presents a conflicted profile with a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between current price ($323.48) and defensive fair value (Graham Number: $175.91). While revenue growth remains robust at 12.3%, the company has suffered a catastrophic collapse in YoY earnings growth (-99.9%), suggesting severe short-term headwinds or one-time accounting shocks. Technical trends are currently bearish (0/100), though a recent one-month bounce and a favorable Forward P/E of 16.08 indicate analyst expectations of a recovery. The stock is currently trading at a significant premium to its intrinsic value, relying heavily on its market dominance and future earnings normalization.